Journal article · 2023 · Open access

POS0839 THE COMPARISON OF MALIGNANCY RISK BETWEEN JAK INHIBITORS AND TNF INHIBITORS IN MULTI-CENTER COHORT STUDY

Tomohisa Uchida, Naoki Iwamoto, Shoichi Fukui, Shimpei Morimoto, Toshiyuki Aramaki, F. Shomura, Koichiro Aratake, Katsumi Eguchi, Yukitaka Ueki, Atsushi Kawakami

Annals of the Rheumatic Diseases, 82, 717–718 · Published 1 June 2023 · DOI 10.1136/annrheumdis-2023-eular.351

Open PDFView at the publisherCite this paper

In brief

“POS0839 THE COMPARISON OF MALIGNANCY RISK BETWEEN JAK INHIBITORS AND TNF INHIBITORS IN MULTI-CENTER COHORT STUDY” is a 2023 journal article by Tomohisa Uchida and 9 co-authors, published in Annals of the Rheumatic Diseases. OpenAlex counts 0 citations as of 19 November 2026. It is open access: the full text is free to read at Annals of the Rheumatic Diseases.

Citations
0
Authors
10

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Uchida, T., Iwamoto, N., Fukui, S., Morimoto, S., Aramaki, T., Shomura, F., Aratake, K., Eguchi, K., Ueki, Y., & Kawakami, A. (2023). POS0839 THE COMPARISON OF MALIGNANCY RISK BETWEEN JAK INHIBITORS AND TNF INHIBITORS IN MULTI-CENTER COHORT STUDY. Annals of the Rheumatic Diseases, 82, 717–718. https://doi.org/10.1136/annrheumdis-2023-eular.351

MLA 9

Uchida, Tomohisa, et al. “POS0839 THE COMPARISON OF MALIGNANCY RISK BETWEEN JAK INHIBITORS AND TNF INHIBITORS IN MULTI-CENTER COHORT STUDY.” Annals of the Rheumatic Diseases, vol. 82, 2023, pp. 717–718. https://doi.org/10.1136/annrheumdis-2023-eular.351.

Chicago

Uchida, Tomohisa, Naoki Iwamoto, Shoichi Fukui, Shimpei Morimoto, Toshiyuki Aramaki, F. Shomura, Koichiro Aratake, Katsumi Eguchi, Yukitaka Ueki, and Atsushi Kawakami. 2023. “POS0839 THE COMPARISON OF MALIGNANCY RISK BETWEEN JAK INHIBITORS AND TNF INHIBITORS IN MULTI-CENTER COHORT STUDY.” Annals of the Rheumatic Diseases 82: 717–718. https://doi.org/10.1136/annrheumdis-2023-eular.351.

Harvard

Uchida, T. et al. (2023) ‘POS0839 THE COMPARISON OF MALIGNANCY RISK BETWEEN JAK INHIBITORS AND TNF INHIBITORS IN MULTI-CENTER COHORT STUDY’, Annals of the Rheumatic Diseases, 82, pp. 717–718. doi:10.1136/annrheumdis-2023-eular.351.

IEEE

T. Uchida et al., “POS0839 THE COMPARISON OF MALIGNANCY RISK BETWEEN JAK INHIBITORS AND TNF INHIBITORS IN MULTI-CENTER COHORT STUDY,” Annals of the Rheumatic Diseases, vol. 82, pp. 717–718, 2023, doi: 10.1136/annrheumdis-2023-eular.351.

BibTeX

@article{uchida2023comparison,
  title     = {{POS0839 THE COMPARISON OF MALIGNANCY RISK BETWEEN JAK INHIBITORS AND TNF INHIBITORS IN MULTI-CENTER COHORT STUDY}},
  author    = {Uchida, Tomohisa and Iwamoto, Naoki and Fukui, Shoichi and Morimoto, Shimpei and Aramaki, Toshiyuki and Shomura, F. and Aratake, Koichiro and Eguchi, Katsumi and Ueki, Yukitaka and Kawakami, Atsushi},
  journal   = {Annals of the Rheumatic Diseases},
  year      = {2023},
  volume    = {82},
  pages     = {717--718},
  doi       = {10.1136/annrheumdis-2023-eular.351},
  url       = {https://doi.org/10.1136/annrheumdis-2023-eular.351}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies

  • cancer risk
  • JAK inhibitors
  • TNF-alpha inhibitors
  • rheumatoid arthritis
  • tofacitinib
  • baricitinib
  • adalimumab
  • etanercept

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Uchida, T., Iwamoto, N., Fukui, S., Morimoto, S., Aramaki, T., Shomura, F., Aratake, K., Eguchi, K., Ueki, Y., & Kawakami, A. (2023). POS0839 THE COMPARISON OF MALIGNANCY RISK BETWEEN JAK INHIBITORS AND TNF INHIBITORS IN MULTI-CENTER COHORT STUDY. Annals of the Rheumatic Diseases, 82, 717–718. https://doi.org/10.1136/annrheumdis-2023-eular.351

How many times has this paper been cited?

0 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Annals of the Rheumatic Diseases: sign in and open the PDF from this page.

Who wrote this paper?

Tomohisa Uchida, Naoki Iwamoto, Shoichi Fukui, Shimpei Morimoto, Toshiyuki Aramaki, F. Shomura, Koichiro Aratake, Katsumi Eguchi, Yukitaka Ueki, Atsushi Kawakami.

What is the DOI of this paper?

10.1136/annrheumdis-2023-eular.351, permanently at https://doi.org/10.1136/annrheumdis-2023-eular.351. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.